Tissue Welding

Thu, 22 May 2008
CSMG Technologies, Inc. (OTCBB: CTGI), a technology management company, announced that its Live Tissue Connect ("LTC") subsidiary has completed the onsite audit portion of the CE Mark registration in accordance with the European Medical Device Directive – 93/42/EEC. LTC announced it has already received their ISO 13485:2003 certification for the design and manufacture of Bipolar Forceps Systems. This Quality Management System certificate was issued by BSI Management Systems, one of the world's leading certification bodies.

Live Tissue Bonding Technology
Tissue Welding
The tissue bonding / welding device is a platform technology that bonds and reconnects living soft biological tissue through fusion without the use of foreign matters or conventional wound closing devices such as sutures, staples, sealant, or glues. The technology leaves little or no scar tissue visible to the naked eye after a few months. Unlike other tissue coagulation methods that tend to destroy tissue by charring, searing and necrosis, the tissue welding patented platform technology bonds and reconnects incised tissue and avoids charring, searing and necrosis, using a low heat delivery method aimed at restoration of the normal functions of the live organs and tissue. The smokeless capability of the tissue welding technology has a significant benefit to the medical professional health services provider because current technologies for R F frequency welding or bonding have significant smoke that the carcinogens have been found carry infectious microorganisms from high risk HIV and Hepatitis patients during surgery.

Robert D. Tucker PhD, MD. Dr. Tucker is with the University of Iowa, Department of Pathology and the Department of Biomedical Engineering. He will be presenting his teams' comparative results with the LTC bipolar sealing system at the 17th annual Congress of the International Society for Gynecologic Endoscopy, the World Congress of Gynecologic Endoscopy and SEGI Annual meeting which will be held in Bari, Italy from June 4th to 7th 2008

FDA still awaiting OK to open China offices

WASHINGTON (AP) — Chinese bureaucracy is slowing U.S. efforts to increase safety monitoring of food and medicine destined for the United States, a top health official said Friday.
The Food and Drug Administration wants to establish foreign offices in three Chinese locations — Beijing, Shanghai and Guangzhou. Thirteen employees would be assigned to work there.
Leavitt said Chinese health officials support the concept of an FDA presence, but the Ministry of Foreign Affairs has yet to give its formal approval. Once it does, the ministry will begin the process of approving diplomatic visas.
"Bureaucracies in their country and in ours never move fast enough for me," Leavitt said. Still, he said he believed that approval for the offices would happen soon.
"This is about giving them better capacity to reach their most important consumer market," he said. "I think they can see that."
Safety issues involving the blood thinner heparin, food and other products imported from China has put pressure on the FDA to boost its international presence. In the heparin case, a Chinese-made component contained a contaminant linked to as many as 81 deaths and hundreds of allergic reactions.
Leavitt envisions an FDA presence around the globe. After China, he said his next priority is an office in India.
"There are 90 to 100 FDA-inspected facilities there producing mostly drugs and medical devices," Leavitt said. "I expect that number to grow. The connection between the U.S. pharmaceutical industry and India is real and expanding. We just need to be there."
Source Associated Press

Haemacure announces webcast of presentation at Rodman & Renshaw 5th Annual Global Healthcare Conference

Haemacure Corporation (TSX:HAE), aspecialty bio-therapeutics company developing high-value human proteins forcommercialization, announced today that its Chairman of the Board and ChiefExecutive Officer, Joseph Galli, will present at the upcoming Rodman & Renshaw5th Annual Global Healthcare Conference on Tuesday, May 20, 2008.

To access the broadcast via internet inlisten-only mode, or the subsequently archived recording, simply cut and pastethe following link directly into your web browser:

http://www.wsw.com/webcast/rrshq13/hae.cn

Vascular Solutions to Present At FBR 12th Annual Spring Investor Conference

MINNEAPOLIS, May 14, 2008 (PRIME NEWSWIRE) -- Vascular Solutions, Inc. (Nasdaq:VASC) today announced that the Company is scheduled to present at FBR Capital Markets' 12th Annual Spring Investor Conference on Wednesday, May 28, 2008 at 1:35pm (EDT).
Howard Root, Chief Executive Officer of Vascular Solutions, will deliver the Company's presentation. To hear the live audio webcast and view the slides of the Vascular Solutions' presentation, go to the investor relations page of the Company's web site http://www.vascularsolutions.com and click on the "IR Conferences" icon a few minutes prior to start time to download any necessary software.

Archive - Baxter gets rights to TachoSil

DEERFIELD, Ill., January 7, 2008 — Baxter Healthcare Corporation today announced an agreement with Nycomed that grants Baxter exclusive rights to market and distribute the company’s TachoSil® patch in the United States. TachoSil is a patented Nycomed product, which is currently available in more than 50 markets outside of the United States including Europe and Japan. The product is a fixed combination of a collagen patch coated with human thrombin and fibrinogen. It is used in a variety of surgical procedures to seal tissue and control bleeding, requires little preparation and can be stored at room temperature. The currently approved indication in Europe is “for supportive treatment in surgery for improvement of hemostasis where standard techniques are insufficient.” TachoSil is not yet an approved product in the United States.

TachoSil® is a ready-to-use surgical patch that allows haemostasis to be achieved quickly and easily. TachoSil® is the only ready-to-use fixed combination of a collagen sponge coated with a dry layer of the human coagulation factors fibrinogen and thrombin. TachoSil® achieves haemostasis in 3-5 minutes and has several distinct advantages compared with current supportive techniques.

Hemostat Technologies

You can find a technology comparitive overview HERE . All downloads are verified safe via Adrive.

Celox

CELOX is an innovative new hemostat designed to bond with specific sites which are present on the surface of red blood cells and platelets to make a gel like clot /plug. This process is totally different from the body’s normal clotting mechanisms. CELOX is a proprietary blend of materials covered by 3 international patent applications.
CELOX contains a natural marine polymer, Chitosan.
Chitosan is a highly purified polysaccharide derivative of shrimp shells.
Chitosan is used widely and is in such products as bandages, medical devices diet aids and some cosmetics. It is an approved food ingredient.

Curamedical

CuraMedical BV is a medical device company operating in the wound management sector and based in the Netherlands. The key strategic goals of CuraMedical are the manufacture and marketing of haemostatic agents and cytological biopsy instruments. CuraMedical’s mission is “To become a leading medical device company specializing in the supply of value-added products in wound management and diagnostics, contributing to public healthcare and focussing on leading edge technology products which are manufactured at a competitive price”. CuraMedical entered the healthcare business in 1995 manufacturing and marketing Curaspon®, an absorbable haemostatic agent based on pharmaceutical gelatin. Nowadays Curaspon® is distributed to more than 60 countries world wide.
Curacel® is a sterile absorbable knitted fabric, prepared by the controlled oxidation of regenerated cellulose.

PTV - Pharma TV a great resource for Companies

I am pleased to offer this link to PTV they are a wonderful resource especially for start-up companies. New companies will definitely appreciate these insights, I highly recommend for excellent insight from market leaders, and detail on financing pitfalls. There are interviews available online with firms in our industry such as Zymogenetics and a great resource for financing and acquisitions information. Please click HERE .

Haemacure Fibrin Market Comparison (featured key slides click to enlarge).

CLICK IMAGE TO ENLARGE

Haemacure Full Investor presentation with Audio available HERE